2020
Mural Cell-Specific Deletion of Cerebral Cavernous Malformation 3 in the Brain Induces Cerebral Cavernous Malformations
Wang K, Zhang H, He Y, Jiang Q, Tanaka Y, Park IH, Pober JS, Min W, Zhou HJ. Mural Cell-Specific Deletion of Cerebral Cavernous Malformation 3 in the Brain Induces Cerebral Cavernous Malformations. Arteriosclerosis Thrombosis And Vascular Biology 2020, 40: 2171-2186. PMID: 32640906, DOI: 10.1161/atvbaha.120.314586.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosis Regulatory ProteinsBrainCell CommunicationCell MovementCells, CulturedCoculture TechniquesEndothelial CellsFemaleFocal AdhesionsGene DeletionGenetic Predisposition to DiseaseHemangioma, Cavernous, Central Nervous SystemHumansMaleMembrane ProteinsMice, KnockoutMicrovesselsMyocytes, Smooth MusclePaxillinPericytesPhenotypeProtein StabilityProto-Oncogene ProteinsSignal TransductionConceptsCerebral cavernous malformationsBrain mural cellsCCM lesionsMural cellsCavernous malformationsSevere brain hemorrhageCCM pathogenesisSmooth muscle cellsWeeks of ageCell-specific deletionMural cell coverageBrain pericytesBrain hemorrhageNeonatal stageBrain vasculatureLesionsEntire brainMuscle cellsCerebral cavernous malformation 3Endothelial cellsMicePericytesSpecific deletionAdhesion formationPathogenesis
2019
CCM3 and cerebral cavernous malformation disease
Wang K, Zhou HJ, Min W. CCM3 and cerebral cavernous malformation disease. Stroke And Vascular Neurology 2019, 4: svn-2018-000195. PMID: 31338212, PMCID: PMC6613868, DOI: 10.1136/svn-2018-000195.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosis Regulatory ProteinsCapillary PermeabilityCell MovementCell ProliferationCerebral ArteriesEndothelial CellsGenetic Predisposition to DiseaseHemangioma, Cavernous, Central Nervous SystemHumansMembrane ProteinsMutationNeovascularization, PathologicPhenotypeProto-Oncogene ProteinsSignal TransductionConceptsCerebral cavernous malformationsSmall blood vesselsTreatment of CCMsCerebral cavernous malformation diseaseBlood vesselsRisk of strokeUnique biological functionsPotential therapeutic strategyFocal neurological defectsCCM proteinsEndothelial cell junctionsCCM3/Vascular lesionsBiological functionsDifferent genesCCM genesCavernous malformationsSevere formTherapeutic strategiesCell junctionsNeurological defectsSimilar functionsMalformation diseaseCCM diseaseDisease
2014
Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis.
Chen X, Zhou HJ, Huang Q, Lu L, Min W. Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymphangiogenesis. Anti-Cancer Agents In Medicinal Chemistry 2014, 14: 946-54. PMID: 24913775, PMCID: PMC5055472, DOI: 10.2174/1871520614666140610102651.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor receptor 3Lysosome-dependent pathwayProteasomal inhibitor MG132Lysosome inhibitor chloroquineGrowth factor receptor 3Transcription factor NF-κBFactor NF-κBInhibitor MG132EC cell linesReceptor essentialThioredoxin reductaseVivo lymphangiogenesisInhibitor chloroquineNovel targetCancer metastasisEC apoptosisCell linesDose-dependent mannerEC proliferationPotent therapeutic agentMechanism of actionDownregulationLymphangiogenesisRheumatoid arthritisPrimary ECs